Minerva Neurosciences, Inc. has provided a significant update regarding its product candidate, roluperidone, which is being developed to treat negative symptoms in patients diagnosed with schizophrenia. The company hosted a key opinion leader event on November 12, 2026, where insights and discussions surrounding the ongoing Phase 3 clinical trial were shared. This event is crucial as it highlights the potential regulatory pathway for the drug, depending on the trial outcomes.

During the event, Frank Sasinowski, the company’s regulatory counsel, participated in discussions about the implications of the trial results and the ongoing conversations with the U.S. Food and Drug Administration (FDA). His insights into the regulatory landscape are particularly important as Minerva Neurosciences seeks to navigate the complexities of drug approval processes. Sasinowski characterized his views on the potential regulatory outcomes should the company receive positive results from the initial 12-week, placebo-controlled portion of the C19 Phase 3 clinical trial.

Minerva Neurosciences, Inc. is a company focused on developing innovative therapies for neuropsychiatric diseases. According to its recent SEC filings, the company operates under the SIC code 2834, which corresponds to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol NERV.

The recent filing, dated November 16, 2026, included a revised transcript of the KOL event as Exhibit 99.1, aimed at clarifying statements made during the discussion. Sasinowski emphasized that his expressions of confidence regarding potential approval are personal opinions and should not be interpreted as guarantees of any future FDA decisions. The company is committed to completing the relapse comparison portion of the C19 trial (Phase B) and intends to engage with the FDA once topline results are available.

Furthermore, the company has updated its investor presentation, which will be used in discussions with investors and analysts, as noted in Item 8.01 of the filing. This presentation is expected to provide additional context and insights into the company’s strategies and the significance of the ongoing clinical trials.

The outcome of the C19 trial is critical not only for Minerva Neurosciences but also for the broader pharmaceutical industry, particularly in the treatment of schizophrenia. The potential approval of roluperidone could represent a significant advancement in addressing the unmet medical needs of patients suffering from negative symptoms associated with this condition.

Looking ahead, the company remains focused on its clinical trials and regulatory discussions. The filing does not specify the next steps following the KOL event, but it indicates that the company is actively pursuing its development goals and maintaining open lines of communication with regulatory bodies.